Navigation Links
Neurocrine Biosciences Reports First Quarter 2012 Results
Date:5/2/2012

hich began in June 2010. During the first quarter of 2012, the Company recognized revenue of $2.0 million in the form of sponsored development funding under these two agreements compared to $3.2 million of sponsored development revenue during the first quarter of 2011.

Research and development expenses increased to $9.4 million during the first quarter of 2012 compared with $7.3 million for the same period in 2011.  The increase in expense was a result of higher external clinical development expenses related to the VMAT2 program, partially offset by lower external clinical development expenses related to the elagolix program. The Company also incurred costs during the first quarter of 2012 related to early stage programs for external testing and scientific consulting that accounted for $0.7 million of the increase. Additionally, research and development personnel expenses were higher quarter over quarter, primarily due to a $0.3 million increase in share-based compensation expense. General and administrative expenses increased from $3.2 million in the first quarter of 2011 to $3.7 million for the first quarter of 2012. This increase is primarily driven by higher share-based compensation expense which increased by $0.4 million.

Pipeline HighlightsElagolix Update
During April 2012, Abbott held the investigator meeting to launch the Phase III program for elagolix in endometriosis. The screening of patients for the Phase III clinical program of elagolix for endometriosis is expected to commence in the second quarter of 2012.

Abbott continues to enroll subjects in a large Phase II study of elagolix in uterine fibroids. This study will assess uterine blood loss in 325 women with heavy uterine bleeding due to uterine fibroids.

VMAT2 Update
The Company's VMAT2 inhibitor, NBI-98854, recently completed a second Phase II study assessing the efficacy of NBI-98854 in tardive dyskinesia patients. The design of th
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2011 The CAQH® Universal Provider Datasource® (UPD®) ... as the go-to resource for complete and reliable ...  Three out of five licensed and practicing physicians ... service. About 7,000 additional providers are registering each ...
... 2011 Instrumentation Laboratory (IL) today announced the appointment ... effective May 1, 2011.  Mr. Benet began his career ... Vice President of Worldwide Marketing, Sales and Service.   ... Josep Manent who served as CEO since 1999.  Under ...
Cached Medicine Technology:900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 2900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 3Instrumentation Laboratory Appoints Ramon E. Benet New Chief Executive Officer 2
(Date:12/24/2014)... 2014 For nearly 20 years, June ... babies, graces, and all of life's rites of passage. ... Nancy Tupper Ling, in Toasts: The Perfect Words ... , Organized by category and containing many original ... anywhere else, this timely tome contains sayings famous and ...
(Date:12/24/2014)... December 24, 2014 Attorneys handling talcum ... an update to their website, the Talcum Powder ... between talcum powder class action lawsuits and ovarian cancer ... and ovarian cancer updates at their website, which serves ... for ovarian cancer claims are not the same as ...
(Date:12/24/2014)... Dr. Ronald Receveur, a New Albany ... dental implants in a day, has written a ... teeth-whitening treatments. , In his blog published Dec. ... writes that overusing teeth-whitening treatments can lead to tooth ... , “Because teeth-whitening treatments are available in ...
(Date:12/24/2014)... Thompson HealthDay Reporter TUESDAY, ... the experimental Ebola vaccine that U.S. officials are preparing to ... precursor of that vaccine produced a safe and potent immune ... when given to more than 100 Ugandans in 2009 and ... that could potentially protect a person against infection by Ebola, ...
(Date:12/24/2014)... -- Long-term fear of terrorists may damage your heart and ... from Israel suggests. , , Conducted by researchers from the ... Israel, the threat of war and terrorism has been a ... wanted to test whether fear of terrorism can predict an ... author Hermona Soreq, a professor of molecular neuroscience, said in ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4Health News:Terrorism Fears May Shorten Your Life, Study Finds 2
... make the best use of the impasse in the US over ... global //hub in that sphere, scientist and entrepreneur Dr William J ... Corp, a leading biopharma and vaccine company in the US, was ... is participating in the BioAsia 2004 summit being held there. ...
... are in terminal decline because of global warming, scientists have ... year revealed that the rate of melting across the world ... glaciers in jeopardy. ,The loss of glaciers ... of millions of people within a few decades, experts warned. ...
... A new study reports that recent decline in breast cancer ... receptor (ER)-positive tumors and women younger than 70//. ... April 2 in the Journal of Clinical Oncology (JCO). ... average age of breast cancer diagnosis is 62. ...
... she wrote it off as just a part of growing ... month// .” ,“I was increasingly having painful menstrual ... 43. ,After running some tests, her doctor discovered ... in 10 women, usually of childbearing age. In addition to ...
... being led to believe that, if they get circumcised, ... a ‘vaccine;’ but it is not a vaccine// and ... false pretenses. ,“The century-old circumcision ‘experiment’ in ... Africa be any different?” asks Dan Bollinger, director of ...
... Prime Minister Girija Prasad Koirala who, despite his indifferent health ... coming to the SAARC summit. ,Addressing the opening ... statesman of Nepal, also used the occasion to confess to ... gambled 60 years of my political career to have a ...
Cached Medicine News:Health News:India Should Take the Lead in Stem Cell Research, Expert 2Health News:Bolivian Glacier Melts, Dangerously Fast 2Health News:Breast Cancer? ER Positive or Negative 2Health News:Hope for Ending the Pain, Infertility of Endometriosis? 2Health News:Hope for Ending the Pain, Infertility of Endometriosis? 3Health News:Promoting Circumcision to Prevent HIV is Misguided and Will Backfire: ICGI 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: